FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.
What happened
FDA inspected TCI Co., Ltd. - BioCosme PABP BRANCH in Pingtung County, Taiwan, from March 9 to March 13, 2026, and found significant CGMP (current good manufacturing practice) violations for over-the-counter drugs. FDA said the firm released OTC drug batches without required active-ingredient strength testing, lacked identity testing for incoming components, did not adequately validate its processes, and had weak quality-unit oversight. FDA reviewed the firm's April 2, 2026, response and found it inadequate because it lacked supporting documentation or adequate evidence of corrective actions.
What FDA found
The company released OTC drug batches without testing the active ingredient's identity and strength before release.
21 CFR 211.165(a)The company did not test incoming ingredients for identity and purity and did not verify suppliers' certificates of analysis at appropriate intervals.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company lacked adequate written procedures for production and process controls and did not properly validate its OTC drug manufacturing processes or qualify a component used in manufacturing and cleaning.
21 CFR 211.100(a)The quality control unit did not ensure compliance, allowed process changes without required change control, had incomplete batch records, and had no written stability testing program.
21 CFR 211.22; 21 CFR 211.188(b); 21 CFR 211.166(a)
What FDA wants
FDA asks the company to respond in writing within 15 business days to CDER-OC-OMQ-Communications@fda.hhs.gov with corrective action documentation and plans covering quality agreements, testing, validation, and quality-unit oversight. If the company resumes drug manufacturing, it must notify FDA before resuming and should use a qualified consultant for a six-system CGMP audit.
Who should pay attention
- brands that buy OTC drug products from this contract manufacturer
- U.S. distributors and retailers of its OTC drugs
- quality teams managing supplier qualification and quality agreements
This is a summary. Read the original letter on fda.gov.